Evidence map›Paper›PMID 42230937›Full record

ArticleScientific reports2026

Changes in peripheral blood T lymphocyte subsets before and after systemic therapy in patients with HER2-positive advanced breast cancer.

Shu Tang, Fen Chen, Qiyuan Zhou, Qianqiu Jiang

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shu TangDepartment of Breast Oncology, Chenzhou No.1 People's Hospital, Chenzhou, 423000, Hunan, China.
Fen ChenRadiotherapy Center, Chenzhou No.1 People's Hospital, Chenzhou, 423000, Hunan, China.
Qiyuan ZhouRadiotherapy Center, Chenzhou No.1 People's Hospital, Chenzhou, 423000, Hunan, China.
Qianqiu JiangDepartment of Pharmacy, Chenzhou No.1 People's Hospital, Chenzhou, 423000, Hunan, China. jqq19781217@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of the immune response in influencing the therapeutic efficacy of systemic therapy for HER2-positive advanced breast cancer remains inadequately defined. This study included 82 patients with HER2-positive advanced breast cancer treated at Chenzhou No.1 People's Hospital from March 2021 to March 2023 as the observation group, alongside 44 age-matched healthy female controls. The observation group received a TCbHP systemic therapy regimen. Peripheral blood T lymphocyte subsets (CD3

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesT-Lymphocyte SubsetsAdultAgedCase-Control StudiesFemaleHumansMiddle AgedNeoplasm StagingERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesAdvanced breast cancerClinical efficacyHER2-positiveT lymphocyte subsets

Identifiers

PMID42230937
PMCPMC13462140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.